Jagsonpal Pharmaceuticals share news, announcements and annual reports
NSE: JAGSNPHARMBSE: 507789Pharmaceuticals & BiotechnologySmall Cap
Jagsonpal Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1987 on BSE, Mar 2000 on NSE
Last close ₹221.94down ₹9.02 (3.91%)BSE ₹221.45
Share price at the NSE close on 29 Oct 2026. Previous close ₹230.96.
29 Oct: open ₹219.52, high ₹231.81, low ₹211.00
52-week range of traded prices to 29 Oct 2026
₹155.00Low, 22 Jan 2026₹264.50High, 30 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,466 Cr1,360th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 32.23
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 6.09
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.80%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,49,04126.1% delivered
Jagsonpal Pharmaceuticals board meetings
121 filed, newest first. Page 3 of 3.
May 2011
4 May · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter/ Year ended on March 31, 2011.
Feb 2011
1 Feb · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter/ period ended on December 31, 2010.
Nov 2010
8 Nov · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter/ year ended on September 30, 2010.
Aug 2010
3 Aug · Board meeting
(1) Consider and Approve the Audited financial results for the quarter/year ended March 31, 2010. (2) Recommend dividend, if any, for the year ended March 31, 2010. (3) Consider and take on record the Un-audited financial results (Provisional) for the quarter ended June 30, 2010.
May 2010
5 May · Board meeting
To consider and take on record the un-audited financial results (provisional) for Quarter/ year ended March 31, 2010.
Jan 2010
20 Jan · Board meeting
To consider and take on record the un-audited financial results (provisional) for the quarter ended December 31, 2009.
Oct 2009
20 Oct · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on September 30, 2009.
Jul 2009
18 Jul · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on June 30, 2009.
Jun 2009
15 Jun · Board meeting
1) To consider and approve the Audited financial results for the quarter / year ended March 31, 2009. 2) Recommend dividend, if any, for the year ended March 31, 2009.
Jan 2009
16 Jan · Board meeting
Meeting on 28 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Oct 2008
20 Oct · Board meeting
Meeting on 31 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Aug 2008
21 Aug · Board meeting
(1) To consider and approve the Audited financial results for the quarter/year ended March 31, 2008.(2) Recommend dividend, if any, for the year ended March 31, 2008.
Jul 2008
17 Jul · Board meeting
To consider and take on record the unaudited financial results (provisional) for quarter ended on June 30, 2008.
Apr 2008
16 Apr · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter/ Year ended on 31.03.2008.
Jan 2008
22 Jan · Board meeting
Meeting on 31 Jan 2008: “Unaudited Financial Results for the qtr ended Dec 31, 2007”
Oct 2007
19 Oct · Board meeting
Meeting on 30 Oct 2007: “Unaudited Financial Results for the Qtr ended Sept 30, 2007”
Aug 2007
16 Aug · Board meeting
To (1) Consider and approve the audited financial results for Quarter/year ended on March 31, 2007 and (2) Recommend Dividend, if any, for the year ended March 31, 2007.
Jul 2007
17 Jul · Board meeting
Meeting on 28 Jul 2007: “Unaudited financial results for quarter ended June 30, 2007”
Apr 2007
21 Apr · Board meeting
To consider and take on record the unaudited financial results (provisional) for Quarter ended on 31.03.2007.
Jan 2007
23 Jan · Board meeting
A meeting of the Board of Direcotrs of the Company is now scheduled to be held on 30th January, 2007 to consider and take on record the unaudited financial results (provisional) for Quarter ended on 31.12.2006. Our earlier notice dated 17.1.2007 (informing date of Board Meeting as 29th January, 2007) may please be treated as cancelled17 Jan · Board meeting
Meeting on 29 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”